Standard treatment for glioblastoma multiforme is surgery followed by radiotherapy and
chemotherapy, generally with temozolomide. However, disease recurs in almost all patients …

Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a member of
the tyrosine kinase superfamily receptor. Gliomas are tumors originating from glial cells …

Recent molecular classification of glioblastoma (GBM) has shown that patients with a
mesenchymal (MES) gene expression signature exhibit poor overall survival and treatment …

Abstract Background This phase I/II trial evaluated the maximum tolerated dose (MTD) and
pharmacokinetics of afatinib plus temozolomide as well as the efficacy and safety of afatinib …

We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase
inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the …

During the last decade, extensive multiplatform genome‐wide analysis has yielded a wealth
of knowledge regarding the genetic and molecular makeup of glioblastoma multiforme …

Background Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic
target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade glioma …

Current first-line treatment regimens combine surgical resection and chemoradiation for
Glioblastoma that provides a slight increase in overall survival. Age on its own should not be …

The aim of the present study was to investigate the available literature regarding the oral
side effects or adverse events associated with targeted cancer therapy. Common oral …

Glioblastoma multiforme (GBM) is highly invasive and uniformly fatal, with median survival<
20 months after diagnosis even with the most aggressive treatment that includes surgery …